Dr. Anthony S. Fauci said the administration was optimistic that “we’re not going to see a repeat of what we saw last year,” when the Omicron variant swept through the country.
Author: Sharon LaFraniere
New Covid Booster Strengthens Immune Response Against Subvariants, Moderna Says
A study suggested that the updated booster shot produced higher levels of neutralizing antibodies against BA.4 and BA.5 than the first booster, the company said.
Study Shows New Covid Booster Improves Protection for Older People, Pfizer Says
Federal officials are hoping that the encouraging results will spur more Americans to get an updated booster before a feared surge in coronavirus cases this winter.
FDA Authorizes Updated Covid Booster Shots For Kids 5 to 11
Regulators authorized the shots for older age groups in late August, but much of the general population appears either unaware or uninterested in them.
Lack of Data Still Blunts US Response to Outbreaks
Major data gaps, the result of decades of underinvestment in public health, have undercut the government response to the coronavirus and now to monkeypox.
Walensky, Citing Botched Pandemic Response, Calls for C.D.C. Reorganization
Among other flaws, the public guidance during the coronavirus pandemic was “confusing and overwhelming,” the agency said.
Biden Administration May Offer Second Coronavirus Boosters to All Adults
The latest, highly contagious variant has driven up hospitalization rates and deepened worries about waning immunity among those vaccinated or boosted months ago.
F.D.A. Panel Debates Covid Vaccines for Youngest Kids
Neither Pfizer’s nor Moderna’s pediatric doses have been tested against the subvariants that may soon be dominant in the U.S.
Pfizer Vaccine Effective in Children Under 5, the F.D.A. Says
Outside experts will make their recommendations this week on how the agency should rule on applications from Pfizer and Moderna to vaccinate the nation’s youngest children.
Moderna’s Covid Vaccine is Effective in Children Under 6, F.D.A. Says
Outside experts will meet next week to decide whether to recommend that the agency authorize the vaccine for kids 6 months and older.